) announced that results from two pivotal phase III studies on
pipeline candidate, secukinumab (AIN457), were published in the N
ew England Journal of Medicine
Novartis is evaluating secukinumab for the treatment of
psoriasis. The results from the studies, ERASURE and FIXTURE,
showed that secukinumab met all primary and key secondary endpoints
at week 12 and showed superiority to
) Enbrel in improving moderate-to-severe plaque psoriasis symptoms
in the FIXTURE study, and was superior to placebo in both
In addition, patients treated with secukinumab also reported
improvements in itching, pain and scaling, compared to placebo at
Week 12, in the ERASURE study.
Moreover, secukinumab showed an acceptable safety profile in
both the studies which was consistent with phase II studies. We
note that Novartis submitted secukinumab to regulatory bodies both
in the U.S. and EU in 2013 for the treatment of psoriasis.
Meanwhile, Novartis is also evaluating secukinumab for arthritic
conditions such as psoriatic arthritis, ankylosing spondylitis and
The successful development and commercialization of secukinumab
for the treatment of psoriasis will further strengthen Novartis'
dermatology portfolio. Novartis already has Xolair in its
dermatology portfolio which is approved for the treatment of
refractory chronic spontaneous urticaria (CSU) in the EU and is
known as refractory chronic idiopathic urticaria (CIU) in the
Novartis, a large cap pharma, currently carries a Zacks Rank#3
(Hold). Some better-ranked large cap pharmas include
Johnson & Johnson
). Both the stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
AMGEN INC (AMGN): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.